- active not recruitingPHASE2
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This study is testing a new cancer medicine called tisotumab vedotin for different solid tumours, including bowel, lung, pancreas, and head and neck cancers. It's looking to see how well it works alone or with other treatments, and what side effects might happen. The study has now moved into a longer-term phase.
United States · Canada · France - active not recruitingPHASE1, PHASE2
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
This study is looking at a new way to treat a type of lung cancer called non-small cell lung cancer. It combines two medicines, amivantamab and capmatinib, to see how well they work together and what the best dose is.
United States · Brazil · Canada - recruitingPHASE2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
This study looks at a new way to give a cancer drug called amivantamab, by injection under the skin instead of through a drip. It aims to see how well it works and if it's safe for people with advanced lung cancer, especially those with specific genetic changes.
United States · Brazil · China - recruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
This study is testing a new drug, rilvegostomig, against a standard treatment, pembrolizumab, for advanced lung cancer. It's for people whose cancer has spread and has high levels of a specific marker called PD-L1. The aim is to see which treatment works better and is safer.
United States · Argentina · Australia - recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
This study looks at how a treatment called amivantamab works for people in the UK with a common type of lung cancer (NSCLC) that has a specific genetic change (EGFR mutation). It's observing real-life results of this treatment.
Austria · Belgium · Czechia - active not recruitingPHASE3
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This study compares a new drug, alectinib, with standard chemotherapy for people with a certain type of lung cancer (ALK-positive non-small cell lung cancer) after surgery. We want to see if alectinib is better at stopping the cancer from coming back and if it's safe.
United States · Australia · Austria - active not recruitingPHASE3
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, selpercatinib, to see if it can stop lung cancer from coming back after surgery or radiation. It's for people with a specific type of non-small cell lung cancer.
United States · Australia · Austria - recruitingPHASE2
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
This study is for people with advanced non-small cell lung cancer that has a specific genetic change (homozygous MTAP deletion) and has progressed after previous treatments. It aims to see how safe and effective a new medicine called Navlimetostat (BMS-986504) is in these patients.
United States · Australia · China - active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
United States · Argentina · Canada - recruitingPHASE3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
This study looks at a new combination treatment, Sigvotatug Vedotin plus pembrolizumab, for a type of lung cancer where a protein called PD-L1 is high. We want to see if this combination works better than pembrolizumab alone to help patients.
United States · Argentina · Australia - recruitingPHASE3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
This study is testing a new drug, olomorasib, for a specific type of lung cancer (NSCLC) with a KRAS G12C gene change. It checks if olomorasib, combined with standard treatments, works better than standard treatments alone for people with either resected or unresectable cancer.
United States · Australia · Austria - active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
This study looks at a new combination treatment for advanced lung cancer. It compares giving a well-known drug (pembrolizumab) with or without an additional drug (sacituzumab govitecan) to see which is better at slowing the cancer's growth and helping people live longer.
United States · Australia · Brazil - active not recruitingPHASE3
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
This study compares two drugs, lorlatinib and crizotinib, for people with a specific type of advanced lung cancer called ALK-positive NSCLC. It aims to see if lorlatinib works better at stopping the cancer from growing for longer. This is for patients who haven't had previous treatment for their advanced cancer.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at two new drug combinations, amivantamab and lazertinib, compared to a standard drug, osimertinib, for people in the UK with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation).
United States · Argentina · Australia - recruitingPHASE1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This study is for adults with advanced cancers in places like the lungs or stomach that are hard to treat or have spread. It's testing a new drug, PF-08046050, to see if it's safe and helps shrink these cancers, sometimes with other medicines.
United States · Canada · China - recruitingPHASE1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
This study is looking at a new medicine called PF-08046876 for people with advanced cancers like bladder, lung, head & neck, oesophageal, or pancreatic cancer. It checks how safe the medicine is and how well it works. The medicine is given through a drip.
United States · Canada · Puerto Rico - recruitingPHASE2
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study looks at new ways to treat advanced lung cancer that has a specific genetic change (EGFR mutation). It tests combinations of new drugs, amivantamab and lazertinib, or amivantamab with standard chemotherapy, to see how well they work.
United States · Belgium · Finland - not yet recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This study looks at two drugs called dabrafenib and trametinib for various cancers with a specific gene change (BRAF V600). These drugs are already approved for some cancers and researchers want to see if they can help people with other rare cancers or cancers with this same change.
United Kingdom - recruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
United States · Australia · Austria - active not recruitingPHASE1, PHASE2
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
This study is testing a new combination of two medicines, amivantamab and docetaxel, for people with advanced non-small cell lung cancer. The aim is to find the best dose and see how well this combination works.
United States · Taiwan · Turkey (Türkiye) - recruitingPHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
This study looks at a new treatment called intismeran autogene, given with pembrolizumab, after surgery for non-small cell lung cancer. We want to see if this combination stops the cancer from coming back compared to pembrolizumab alone.
United States · Argentina · Australia - recruitingPHASE2
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
This study is looking at a new treatment called JNJ-90301900 for a type of lung cancer. It combines this new drug with standard chemotherapy, radiation, and another immunotherapy to see if it helps more people get better.
United States · Australia · Brazil - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This study is for adults with specific cancers that have a change called BRAF V600. It's testing if two drugs, vemurafenib and cobimetinib, already used for a type of skin cancer, can help treat these other cancers. The goal is to find new treatments for patients.
United Kingdom - active not recruitingPHASE3
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This study is looking at new ways to treat early-stage lung cancer that hasn't spread. It's testing if a drug called durvalumab, or another drug called osimertinib, when given after standard radiation therapy, can help improve outcomes for patients.
United States · Australia · Belgium - recruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
United States · France · South Korea - active not recruitingPHASE3
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
This study looks at new drug combinations for advanced lung cancer (non-small cell lung carcinoma) that has specific genetic changes (EGFR mutation) and has stopped responding to a previous treatment called osimertinib. It compares these new drug combinations with standard chemotherapy.
United States · Argentina · Belgium - active not recruitingPHASE3
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
This study looks at a new combination of treatments for a type of advanced lung cancer. It compares a drug called amivantamab plus standard chemotherapy to chemotherapy alone, to see if the combination works better at stopping the cancer from growing.
United States · Australia · Belgium - recruitingPHASE1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study is testing a new drug, PF-08046054/SGN-PDL1V, alone and with an existing medicine called pembrolizumab, for various advanced cancers. Researchers want to see how safe it is and if it has any effect on the cancer. It's a very early stage study.
United States · Belgium · Canada - active not recruitingPHASE1, PHASE2
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
This study looks at a new combination of two medicines, amivantamab and cetrelimab, for advanced lung cancer. It aims to find the best dose and see how well it works in people whose cancer has spread and who have already had other treatments.
United States · Brazil · Italy - active not recruitingPHASE2
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This study looks at how a drug called tucatinib, combined with trastuzumab, works for various cancers that have a specific change (alteration) in their HER2 gene. It focuses on cancers that have spread or can't be fully removed by surgery.
United States · Belgium · Germany - recruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
This study is testing a new drug, UCB4594, for advanced cancers. It's the first time it’s being used in people. Researchers want to find the safest dose, understand side effects, and see if it can shrink certain tumours by helping the body's immune system.
United Kingdom - active not recruitingPHASE2
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
This study is testing a new drug, disitamab vedotin, for certain advanced cancers like head and neck, lung, ovarian, and endometrial cancer. It's for people whose cancer has a marker called HER2 and has already been treated. The study wants to see how well the new drug works and if it's safe.
United States · Australia · Canada - active not recruitingPHASE1, PHASE2
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
This study is testing a new medicine, TAK-788 (also known as mobocertinib), for adults with a type of lung cancer. Researchers want to find the best dose, check for side effects, and see how it works in the body.
United States · China · Germany - active not recruitingPHASE3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
This study compares a new cancer drug called sigvotatug vedotin with a standard treatment, docetaxel, for advanced non-small cell lung cancer that has previously been treated. It aims to see if the new drug works better and what side effects it might cause.
United States · Argentina · Australia